Veerendra Munugalavadla

5PUBLICATIONS
50CO-AUTHORS
Molecular targetsIntensive careCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Dec 22, 2025
Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL).

Daniel J Hodson, Geoffrey Shouse, Ho-Jin Shin

|Jun 03, 2025
Efficacy and safety of acalabrutinib with best supportive care versus best supportive care in patients with COVID-19 requiring hospitalization.

Phillip Scheinberg, Matt R Khoshnevis, Philip A Robinson

|Jun 26, 2023
Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker Assessment.

Mark Roschewski, Manish R Patel, Patrick M Reagan

|Jun 05, 2023
Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia.

Wojciech Jurczak, Nagah Elmusharaf, Christopher P Fox

|Feb 16, 2022
Idelalisib reduces regulatory T cells and activates T helper 17 cell differentiation in relapsed refractory patients with chronic lymphocytic leukaemia.

Deepti Gadi, Alec Griffith, Zixu Wang

Pageof 1

Frequent Collaborators

1 joint publications

Jennifer R Brown

1 joint publications

Wojciech Jurczak

1 joint publications

Christopher P Fox

1 joint publications

William Townsend